NVP-ADW742 is primarily used in cancer research as a small-molecule antagonist of the insulin-like growth factor receptor (IGF-1R) pathway. It demonstrates potent anti-tumor activity by inhibiting IGF-1R signaling, which plays a key role in cell proliferation, survival, and metastasis in various cancers. This compound has been investigated in preclinical studies for its ability to induce apoptosis and reduce tumor growth, particularly in models of sarcoma, lung cancer, and other malignancies dependent on IGF signaling. Its application is mainly confined to experimental oncology, where it serves as a tool compound for validating IGF-1R as a therapeutic target and for studying mechanisms of drug resistance.